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Association of rare variation in the glutamate receptor
gene SLC1A2 with susceptibility to bipolar disorder
and schizophrenia
Alessia Fiorentino1, Sally I Sharp1 and Andrew McQuillin*,1
The SLC1A2 gene encodes the excitatory amino acid transporter 2 (EAAT2). Glutamate is the major mediator of excitatory
neurotransmission and EAAT2 is responsible for clearing the neurotransmitter from the synaptic cleft. Genetic variation in
SLC1A2 has been implicated in a range of neurological and neuropsychiatric conditions including schizophrenia (SZ), autism
and in core phenotypes of bipolar disorder (BD). The coding and putative regulatory regions of SLC1A2 gene were screened for
variants using high resolution melting or sequenced in 1099 or in 32 BD subjects. Thirty-two variants were detected in the
SLC1A2 gene. Fifteen potentially etiological variants were selected for genotyping in 1099 BD and 1095 control samples. Five
amino acid changing variants were also genotyped in 630 participants suffering from SZ. None of the variants were found to be
associated with BD or SZ or with the two diseases combined. However, two recurrent missense variants (rs145827578:G4A,
p.(G6S); rs199599866:G4A, p.(R31Q)) and one recurrent 5′-untranslated region (UTR) variant (ss825678885:G4T) were
detected in cases only. Combined analysis of the recurrent-case-only missense variants and of the case-only missense and
5′-UTR variants showed nominal evidence for association with the combined diseases (Fisher’s P=0.019 and 0.0076).
These ﬁndings are exploratory in nature and await replication in larger cohorts, however, they provide intriguing evidence
that potentially functional rare variants in the SLC1A2 gene may confer susceptibility to psychotic disorders.
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INTRODUCTION
Glutamate is considered to be the major mediator of excitatory
neurotransmission in the central nervous system. At high extracellular
concentrations, glutamate can induce neuronal cell death by a
complex mechanism termed excitotoxicity.1 Extracellular glutamate
is predominantly cleared by the solute carrier 1 (SLC1) family of
proteins. This family of proteins comprises ﬁve high-afﬁnity glutamate
transporters (excitatory amino acid transporter 3 (EAAT3), EAAT2,
EAAT1, EAAT4 and EAAT5) and two amino acid transporters
(ASCT1 and AAAT). SLC1A2 encodes EAAT2, which is also known
as the glial high-afﬁnity glutamate transporter GLT1 in the mouse. It
has a crucial role in removing glutamate from the synaptic cleft and
has been found to be responsible for about 90% of total glutamate
uptake in most brain areas.2,3 This process modulates the termination
of glutamatergic synaptic signalling and prevents excitotoxic effects of
glutamate on post-synaptic neurones. EAAT2 is predominantly
expressed in astrocytes under normal conditions.4 It is also detected
in oligodendrocytes and in neurons4–7 throughout the spinal cord and
the brain, particularly in the cerebral cortex and hippocampus.8 The
SLC1A2 gene consists of 11 protein-coding exons and spans more than
50kb of genomic DNA on chromosome 11p13-12.9 Several post-
transcriptionally regulated forms of EAAT2 have been identiﬁed.
Alternative splicing of the 5′-a n d3 ′-untranslated regions (UTRs)
produces different mRNA isoforms10–14 as well as proteins with
different amino- (N-) and carboxy- (C-) termini.15–17 The 3′-UTR
has a variety of regulatory elements14 including enhancers, AU-rich
elements, as well as putative polyadenylation sites. AU-rich elements
deﬁne the cytoplasmatic half-life of mRNA molecules18,19 and poly-
adenylation is essential for nuclear mRNA export, translation and
control of mRNA decay.20,21 Besides diverse N- and C-termini, exon-
skipping splice variants of EAAT2 have been described in brain tissue
samples and these include: an exon 5 and 6 partial deletion,22 an exon
7 deletion,23 an exon 8 deletion,24 an exon 9 deletion25 and an exon 7
and 9 deletion.26 Evidence of epigenetic regulation of human EAAT2
transcription based on methylation of the promoter has also been
identiﬁed.27,28
Dysregulation of EAAT2 is associated with several neurological
diseases including amyotrophic lateral sclerosis,29 Alzheimer’s disease,
epilepsy, as well as several psychiatric diseases such as schizophrenia
(SZ), depression30 and autism.31,32 The SLC1A2 SNP rs3794087 was
found to be associated with essential tremors in a GWAS study.33
However, this ﬁnding has not been consistently replicated.34–37
There is evidence which suggests that alterations in the glutama-
tergic systems may contribute to the pathophysiology of depression,38
with elevated levels of glutamate observed in the cerebral cortex of
depressed patients.39 Glutamate signalling is involved in neurological
mechanisms implicated in the etiology of bipolar disorder (BD) such
as brain development and synaptic plasticity.40 In post-mortem brain
tissue from BD patients, altered levels of glutamate/glutamine,
N-methyl-D-aspartate receptors41 and SLC1A2 protein and mRNA42
have been found. Reduced expression of the membrane transporter
SLC1A2 was also reported in major depression while a trend in the
same direction has been observed in BD subjects.43 Differential
expression of SLC1A2 in the locus coeruleus has been reported in
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www.nature.com/ejhgmajor depression but not in BD subjects.44 Two SNPs in SLC1A2 have
been reported to be associated with the core phenotypes of BD:
rs4755404:C4G was reported to be associated with attempted
suicide45 and rs4354668:A4C was reported to inﬂuence the total
episode recurrence rate and the efﬁcacy of lithium treatment response
in a sample of Italian patients with BD.46 rs4354668:A4Ci sa
functional polymorphism and was shown to signiﬁcantly inﬂuence
grey matter volume in BD subjects with low adverse childhood
experiences, with the wild-type T homozygote presenting the lowest
volume, the G homozygote reporting the highest volume and
heterozygotes showing an intermediate phenotype.47 The same SNP
has a similar effect in a group of SZ subjects: carriers of the G allele
had lower grey matter volumes and worse working memory perfor-
mance than T/T homozygotes.48 Signiﬁcant dysregulation of SLC1A2
expression in the dorsolateral prefrontal cortex in BD and SZ subjects
compared with control individuals has been reported.49 Decreased
EAAT2 protein levels were found in the superior temporal gyrus and
in the hippocampus of SZ subjects50 and EAAT2 glycosylation was
found to be altered in patients with SZ compared with controls.51
Allelic association between SLC1A2 and BD was detected by our
laboratory in the UCL-STEPBD genome-wide association study
(GWAS).52 In the UCL sample 10 markers within the gene showed
P-values ranging from 0.0011 to 0.038.
MATERIALS AND METHODS
Subjects
This study included 1099 affected BD research subjects and 630 subjects
affected with SZ. Ancestry screening was used as a selection criterion for the
inclusion of cases and screened controls. Samples were included if at least three
out of four grandparents were English, Irish, Scottish or Welsh and if the fourth
grandparent was non-Jewish European, before the EU enlargement in 2004. All
SZ cases were selected for having prior International Classiﬁcation of Diseases
10 (ICD10) diagnosis of SZ made by National Health Service (NHS)
psychiatrists. The BD cases were sampled in two cohorts. The ﬁrst cohort,
UCL1, includes 506 Bipolar 1 (BP1) research subjects deﬁned by the presence
of mania and hospitalisation according to research diagnostic criteria (RDC).53
The second cohort, UCL2, consists of 593 subjects with BP1 or BP2. BD and SZ
research subjects had been given a clinical diagnosis of ICD-10 BD or SZ and
were needed to fulﬁl the criteria for the lifetime version of the SZ and Affective
Disorder Schedule (SADS-L),54 which provides RDC.53 T h es a m p l eo f1 0 9 5
controls comprised 615 screened subjects who had no ﬁrst degree family or
personal history of psychiatric illness and an additional 480 unscreened normal
British subjects obtained from the European Collection of Animal Cell Cultures
(ECACC). NHS multicentre research ethics approval was obtained. All
participants provided signed consent.
DNA samples were collected from blood samples from the UCL1, SZ and
control cohorts, and from saliva samples from the UCL2 cohort. DNA from
blood samples was extracted using standard phenol–chloroform method and
from saliva samples using the Oragene protocol for DNA extraction (DNA
Genotek, Ottowa, ON, Canada).
Detection and evaluation of new variants
High resolution melting (HRM) variant screening was used to identify BD
susceptibility variants in the coding exons, 5′-UTR, intron/exon junctions and
the putative promoter region (500bp from the 5′-UTR (chr11: 35441106-
35441687 GRCh37/hg19) of the main isoform ENSP00000278379). HRM was
performed using 18 primer pairs in 1099 BD cases. Reactions were carried out
on a LightCycler 480 (Roche, Burgess Hill, UK). Primer sequences and reagents
are shown in Supplementary Table 1. Samples with abnormal HRM curves
were then sequenced using the Big Dye terminator v3.1 Cycle Sequencing kit
(Applied Biosystems, Warrington, UK) on an ABI 3730xl DNA Analyzer
(Applied Biosystems). Sequencing data was analysed using the Staden
Package.55 Variants that were not previously reported were submitted to
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/). All variant identiﬁers are shown
in Table 1.
Thirty-two BD cases were selected from among those cases who had
inherited an SLC1A2 haplotype of rs7105037, rs7105418, rs4756201,
rs3794099, rs1042113, rs3818275, rs41352148, rs11033052, rs2281634,
rs4756208, rs2421765 and rs379408952 that was associated with BD. Samples
were selected for sequencing on the basis of being carriers of the alleles
5′-GCCCTTACCAAA-3′ for the SNPs listed above. Sequencing was carried out
on the putative promoter region as deﬁned above, the 5′-UTR and the 3′-UTR
(primers in Supplementary Table 2). Sequencing was performed as
described above.
Non-synonymous variants, intron/exon junction variants and SNPs in the
putative regulatory region, whose minor allele frequency was unknown or
o0.01 in the 1000 genomes project (release 20110521),56 were considered for
further analysis.
Bioinformatic analysis, to determine potentially functional SNPs, was carried
out using the UCSC genome browser (http://genome.ucsc.edu/), TESS (http://
www.cbil.upenn.edu/cgi-bin/tess/tess), PolyPhen257 (http://genetics.bwh.harvard.
edu/pph2/), SIFT (http://sift.jcvi.org/), Splice Site Prediction by Neural Network
(http://www.fruitﬂy.org/seq_tools/splice.html), miRanda (http://www.microrna.
org/microrna/home.do) and targetscan 6.2 (http://www.targetscan.org/).
Genotyping
Genotyping of the selected SNPs in 1099 BD cases and 1095 ancestrally
matched controls was performed in-house with allele-speciﬁc PCR using
KASPar reagents (LGC Genomics, Hoddesdon, UK) on a LightCycler 480
(Roche) real-time PCR machine. The non-synonymous variants were also
genotyped in 630 SZ samples. For all SNPs genotyped, 17% of samples were
duplicated to detect error and conﬁrm reproducibility of genotypes. Allele-
speciﬁc primers were designed for each of the SNPs using Primer Picker (LGC
Genomics) as shown in Supplementary Table 3. All these data were analysed to
conﬁrm Hardy–Weinberg equilibrium (HWE). Allelic association analysis of
single variants was performed using PLINK (v1.07)58 and these were
supplemented with Fisher’s exact tests when cell frequencies were o10. The
data for recurrent-case-only variants were combined and tested for association
with BD and SZ against the control subjects using a Fisher’s exact test.
Signiﬁcance values shown for all analyses are uncorrected for multiple testing
and a cut-off signiﬁcance value of Po0.05 was used.
RESULTS
Variant selection
A total of 32 SNPs were detected by HRM analysis across the putative
promoter region, 5′-UTR, exons, intron/exon junctions of SLC1A2 and a
further 8 SNPs were detected by sequencing analysis of 5′-a n d3 ′-UTR
regions (Table 1). These included ﬁve synonymous coding base
pair changes, ss825678894:C4T, rs752949:G4A, rs1042113:A4G,
rs16927239:C4T and rs139804773:C4T; ﬁve non-synonymous coding
base pair changes, rs145827578:G4A, ss825678885:G4T, rs199599866:
G4A, ss825678893:C4T and ss825678895:C4T; ten SNPs in introns,
rs5791053:-4T, rs55643101:T4G, ss825678886:A4G, rs2273687:C4G,
rs2273686:C4T, rs56028027:A4G, rs3895234:T4C, rs116776036:C4T,
rs2273689:T4C and ss825678896:G4T; one variant in intron/exon
junctions, rs56205617:G4A ;s e v e nS N P si nt h e5 ′-UTR, rs111885243:
C4A, rs4354668:A4C, rs116392274:C4A, ss825678882:A4G,
ss825678883:C4G, ss825678884:G4A, rs1885345:T4C; nine SNPs in
the 3′-UTR, rs1570216:A4G, rs10742339:T4A, rs147294857:C4T,
rs10768121:T4G, ss825678897:A4G, rs12361171:A4T, rs3812779:
C4T, rs1043101:T4C, rs3088168:A4G; and three putative promoter
SNPs, rs77619780:G4A, ss825678881:G4C and rs11033118:C4T. Non-
synonymous variant ss825678885:G4T in the uc021qfy.1 isoform is also a
5′-UTR variant in the ENSP00000379099 isoform.
Non-synonymous variants, intron/exon junction variants and SNPs
in the putative regulatory region, whose minor allele frequency was
unknown or o0.01, were considered for further analysis.
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and 9 unknown variants. Two known and one previously unknown
variant were present in the putative promoter region (rs77619780:
G4A, ss825678881:G4C and rs11033118:C4T), three previously
unknown variants were in the 5′-UTR (ss825678882:A4G,
ss825678883:C4G and ss825678884:G4A), two known and three
previously unknown SNPs were non-synonymous (rs145827578:
G4A, ss825678885:G4T, rs199599866:G4A, ss825678893:C4T
and ss825678895:C4T), one known variant was in an intron/exon
junction (rs56205617:G4A) and two known variants and one
previously unknown variant were in the 3′-UTR (rs147294857:
C4T, ss825678897:A4G and rs3812779:C4T).
Bioinformatics analysis of putative promoter and 5′-UTR region
SNPs for altered transcription factor binding indicated that the mutant
alleles were more likely to bind to a decreased range of transcription
factors compared with their respective common alleles. rs77619780:
G4A was predicted to destroy a binding site for three transcription
factors (CCAAT/enhancer-binding protein alpha, Upstream stimula-
tory factor, Speciﬁcity protein 1 (Sp1)), ss825678881:G4Cw a s
predicted to destroy a binding site for one transcription factor (Sp1)
and ss825678883:C4G was predicted to destroy a binding site for two
transcription factors (Early growth response protein 1 and Wilms
tumor protein). rs11033118:C4T and ss825678884:G4Aw e r en o t
predicted to alter transcription factor binding sites, while ss825678882:
A4G was predicted to create a binding site for the Sp1 transcription
factor.
rs145827578:G4A causes a non-conservative amino acid change
from glycine to serine at position 6 (p.(G6S)) of the main isoform.
The p.(G6S) amino acid substitution was predicted to be ‘benign’ with
a score of 0.439 (sensitivity: 0.89 and speciﬁcity: 0.90) by PolyPhen-2
Table 1 SNPs detected by HRM and sequencing analysis across the putative promoter region, 5′-UTR, exons, intron/exon junctions 3′-UTR
regions of SLC1A2 (GRCh37/hg19)
SNP Position on chr11 Variants 1000G MAF Position in gene
ss825678881:G4C 35441380 G4C ND Putative promoter
rs77619780:G4A 35441311 G4A 0.01 Putative promoter
rs11033118:C4T 35441254 C4T 0.01 Putative promoter
rs111885243:C4A 35440995 C4A0 . 3 9 5 ′-UTR
rs4354668:A4C 35440976 A4C0 . 5 9 5 ′-UTR
rs116392274:C4A 35440963 C4A0 . 0 2 5 ′-UTR
ss825678882:A4G 35440927 A4GN D 5 ′-UTR
ss825678884:G4A 35440635 G4AN D 5 ′-UTR
ss825678883:C4G 35440563 C4GN D 5 ′-UTR
rs145827578:G4A 35440498 G4A ND Exonic, non-synonymous
rs5791053:-4T 35392657 -4T 0.52 Intronic
rs1885345:T4C 35392601 T4C0 . 8 7 5 ′-UTR
rs55643101:T4G 35392472 T4G 0.01 Intronic
ss825678885:G4T 35344202 G4T ND Exonic, non-synonymous/5′-UTR
rs56205617:G4A 35344107 G4A 0.03 Intron/exon junction
ss825678886:A4G 35344064 A4G ND Intronic
ss825678893:C4T 35339061 C4T ND Exonic, non-synonymous
rs199599866:G4A 35338989 G4A ND Exonic, non-synonymous
rs2273686:C4T 35338902 C4T 0.15 Intronic
rs2273687:C4G 35338893 C4G 0.21 Intronic
ss825678894:C4T 35336643 C4T ND Exonic, synonymous
rs56028027:A4G 35334032 A4G 0.25 Intronic
rs3895234:T4C 35327825 T4C 0.23 Intronic
rs116776036:C4T 35327804 C4T 0.01 Intronic
rs752949:G4A 35327748 G4A 0.23 Exonic, synonymous
rs2273689:T4C 35323200 T4C 0.59 Intronic
rs1042113:A4G 35308369 A4G 0.27 Exonic, synonymous
rs139804773:C4T 35302500 C4T 0.00 Exonic, synonymous
rs16927239:C4T 35302467 C4T ND Exonic, synonymous
ss825678896:G4T 35282548 G4T ND Intronic
ss825678895:C4T 35282452 C4T ND Exonic, non-synonymous
rs1570216:A4G 35282334 A4G0 . 1 4 3 ′-UTR
rs10742339:T4A 35281100 T4AN D 3 ′-UTR
rs147294857:C4T 35280227 C4T0 . 0 1 3 ′-UTR
rs10768121:T4G 35279656 T4G0 . 3 4 3 ′-UTR
ss825678897:A4G 35279202 A4GN D 3 ′-UTR
rs12361171:A4T 35278333 A4T0 . 3 4 3 ′-UTR
rs3812779:C4T 35276479 C4T0 . 0 0 3 ′-UTR
rs1043101:T4C 35274829 T4C0 . 3 4 3 ′-UTR
rs3088168:A4G 35273268 A4G0 . 3 4 3 ′-UTR
Abbreviations: Chr, chromosome; HRM, high resolution melt; MAF, minor allele frequency; ND, not detected; SNP, single nucleotide polymorphism; UTR, untranslated region.
Variants, the base change indicated is on the negative strand.
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the ENSP00000476124 isoform is predicted to be ‘possibly damaging’
with a score of 0.575 (sensitivity: 0.88 and speciﬁcity: 0.91) by
Polyphen2 (Table 2). In this isoform, 11 amino acids substitute the
last 22 amino acids of the ENSP00000278379 isoform.
rs199599866:G4A causes a non-conservative amino acid change
from arginine to glutamine at position 31 (p.(R31Q)) of the main
isoform. The p.(R31Q) amino acid substitution was predicted to be
‘benign’ with a score between 0 and 0.003 depending on the isoform
(sensitivity: 0.99; speciﬁcity: 0.30) by PolyPhen-2, and ‘tolerated’ with
a score between 0.191 and 0.215 depending on the isoform by SIFT.
The variant ss825678893:C4T causes an alanine to valine substitu-
tion in position 7 (p.(A7V)) of the main isoform and the SNP
ss825678895:C4T causes a non-conservative amino acid change from
arginine to cysteine in position 572 (p.(R572C)) of the main isoform.
The two new non-synonymous variants were predicted to be ‘probably
damaging’ by PolyPhen2 and ‘damaging’ by SIFT in the main isoform.
ss825678885:G4T causes a substitution from alanine to serine at
position 20 (p.(A20S)) of the alternative isoform uc021qfy.1. This
isoform is a non-RefSeq transcript and it was not possible to predict
the effect that the variant may have on protein structure or function
using Polyphen2 or SIFT. In the ENSP00000379099 isoform the
variant is in the 5′-UTR and was predicted to create a binding site for
three transcription factors (estrogen receptors, Chicken Ovalbumin
Upstream Promoter transcription factor and Sp1).
The intron/exon junction variant rs56205617:G4A was predicted
to destroy the donor site of the second exon ENSE00003694146 of the
isoform ENSP00000379099 by the BDGP splice site predictor
programme.
Of the three variants in the 3′-UTR, only the previously unreported
SNP ss825678897:A4G was predicted to alter the binding site for two
microRNA species— miR-664 and miR-664b.
Genotyping
Assays were designed for 15 SNPs, which passed ﬁltering tests for
genotyping in the complete UCL BD case-control sample. Five non-
synonymous SNPs were also genotypes in 630 SCZ samples.
rs145827578:G4A was detected in three BD and two SZ samples
and not in any of the control subjects. These data were not
signiﬁcantly associated with either disease on their own or in a
combined analysis. None of the others variants were found to be
associated with BD, as shown in Table 3.
When the data for case-only recurrent missense variants
rs145827578:G4A (p.(G6S)) and rs199599866:G4A (p.(R31Q)) in
BD and SZ were combined in a burden test there was evidence for
association with the two diseases (Fisher’s P=0.0458; see Table 4). In
a further analysis the data from a third case-only variant ss825678885:
G4T( 5 ′-UTR of uc021qfy.1 isoform and p.(A20S) in the isoform
ENSP00000379099) was added to data for the missense variants and
this also showed evidence for association with the combined diseases
(Fisher’s P=0.0189; see Table 4).
rs4354668:A4C was found to inﬂuence the efﬁcacy of lithium in a
sample of Italian patients with BD.46 Case–case analysis showed that
there is no association between the efﬁcacy of lithium and rs4354668:
A4C in our BD sample (P=0.74; OR=0.94).
rs4755404:C4G has been found to be associated with attempted
suicide in a sample of psychiatric patients recruited in six Community
Psychiatric Clinics in Ireland.45 Imputation of this SNP in GWAS data
from the UCL1 BD cohort52,59 was performed using the 1000 genome
project data56 as a reference. These data were then analysed in a case
versus case design with suicide attempt as the phenotype. In the UCL
BD cohort there were 214 suicide attempters and 83 people recorded
as never having attempted suicide. There was no evidence for
association of rs4755404:C4G with attempted suicide in our sample
(P=0.31).
DISCUSSION
The glutamate neurotransmission pathway has been implicated
genetically and biologically in BD. The crucial role SLC1A2 has in
the uptake of the glutamate from the synaptic cleft and the previous
genetic implication of the gene in BD suggests that this gene represents
a potentially interesting gene to be studied in our BD and SZ cohorts.
The complexity of SLC1A2 regulatory elements including alternative
splicing of both the 5′-a n d3 ′-UTR,10–14 protein isoforms with
different N- and C-termini,15–17 enhancers, AU-rich elements, puta-
tive polyadenylation sites, exon-skipping splice variants and evidence
of epigenetic regulation of human EAAT227,28 underline the impor-
tance of the ﬁne tuning of this gene.
The importance of the ﬁne regulation of this gene and the biphasic
nature of BD makes a compelling argument for the existence of
genetically determined pathological switch mechanisms, which may
manifest themselves in the loss of control of gene expression. This led
us to study not only the protein coding regions of the gene but also the
putative regulatory regions including the 5′-UTR, the 3′-UTR, splicing
Table 2 Polyphen 2 and SIFT prediction of coding non-synonymous variants in the different isoforms of SLC1A2
SLC1A2 isoforms
ENSP00000278379 ENSP00000379102 ENSP00000379099 ENSP00000476124
Variant aa changed Programme Prediction Score Prediction Score Prediction Score Prediction Score
rs145827578:G4A p.(G6S) Polyphen 2 Benign 0.439 Possibly Damaging 0.575
SIFT Tolerated 0.056
ss825678885:G4T p.(A20S) Polyphen 2
SIFT
ss825678893:C4T p.(A7V) Polyphen 2 Probably Damaging 0.993 Probably Damaging 0.996
SIFT Damaging 0.015
rs199599866:G4A p.(R31Q) Polyphen 2 Benign 0.002 Benign 0.000 Benign 0.002 Benign 0.003
SIFT Tolerated 0.191 Tolerated 0.215 Tolerated 0.215
ss825678895:C4T p.(R572C) Polyphen 2 Probably Damaging 0.978 Probably Damaging 0.978 Probably Damaging 0.978
SIFT Damaging 0.003 Damaging 0.003
Abbreviation: aa, amino acid.
aa change, the amino acid change indicated is the one in the ENSP00000278379 isoform for the variants rs145827578:G4A, ss825678893:C4T, rs199599866:G4A and ss825678895:C4T;
the amino acid change indicated is the one in the uc021qfy.1 isoform for the variant ss825678885:G4T.
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and previously unreported variants. The variants that passed ﬁltering
were all genotyped in our BD and control cohorts.
SLC1A2 has also been implicated in susceptibility to SZ and
therefore the non-synonymous variants were also genotyped in our
SZ cohort. The majority of the variants that were genotyped here were
rare and none of the variants on their own were signiﬁcantly
associated with either BD or SZ. However, rs145827578:G4Ah a s
been found in three BD and two SZ patients and was absent in our
control cohort. This variant causes a non-conservative amino acid
change from p.(G6S) of the main isoform. Two other SLC1A2
N-terminal non-synonymous variants in the main isoform were
also detected in this study; case-only variant rs199599866:G4A
(p.(R31Q)) was detected in one BD case and one SZ case; and
Table 3 Tests of association with SLC1A2 variants in BD and SZ
Position on chr11 Position in gene Change N Genotype count MAF P OR (95%CI)
ss825678881:G4C 35441380 Putative promoter G4C 934 BD 0/3/931 0.0016 0.500 0.757 (0.1692–3.386)
943 CTRL 0/4/939 0.0021
rs77619780:G4A 35441311 Putative promoter G4A 931 BD 1/19/911 0.0114 0.615 1.176 (0.6246–2.215)
937 CTRL 1/16/920 0.0096
rs11033118:C4T 35441254 Putative promoter C4T 931 BD 0/20/911 0.0108 0.900 0.961 (0.5193–1.779)
940 CTRL 1/19/920 0.0112
ss825678882:A4G 35440927 5′-UTR A4G 932 BD 0/3/929 0.0016 0.305 3.039 (0.3158–29.24)
943 CTRL 0/1/942 0.0005
ss825678884:G4A 35440635 5′-UTR G4A 934 BD 0/2/932 0.001 0.492 2.018 (0.1828–22.28)
942 CTRL 0/1/941 0.0005
ss825678883:C4G 35440563 5′-UTR C4G 934 BD 0/1/933 0.0005 0.493 NA
941 CTRL 0/0/941 0
rs145827578:G4A 35440498 Exonic p.(G6S) G4A 1073 BD 0/3/1070 0.0013 0.149 NA
631 SZ 0/2/629 0.0015 0.160 NA
1704 BD+SZ 0/5/1699 0.0014 0.111 NA
943 CTRL 0/0/943 0
ss825678885:G4T 35344202 Exonic p.(A20S) 5′-UTR G4T 1075 BD 0/2/1073 0.0009 0.281 NA
626 SZ 0/0/626 0.0007 NA NA
1701 BD+SZ 0/2/1699 0.0005 0.415 NA
944 CTRL 0/0/944 0
rs56205617:G4A 35344107 Intronic G4A 931 BD 1/53/877 0.0304 0.336 1.215 (0.8168–1.807)
941 CTRL 1/44/896 0.025
ss825678893:C4T 35339061 Exonic p.(A7V) C4T 1072 BD 0/1/1071 0.0004 0.785 0.874 (0.05463–13.98)
625 SZ 0/0/625 0 1.00 NA
1697 BD+SZ 0/1/1696 0.0002 0.874 0.553 (0.0345–58.84)
937 CTRL 0/1/936 0.0005
rs199599866:G4A 35338989 Exonic p.(R31Q) G4A 1065 BD 0/1/1064 0.0004 1.000 NA
626 SZ 0/1/625 0.0007 0.398 NA
1791 BD+SZ 0/2/1689 0.0005 0.415 NA
940 CTRL 0/0/940 0
ss825678895:C4T 35282452 Exonic p.(R572C) C4T 1072 BD 0/2/1070 0.0009 0.737 0.879 (0.1236–6.243)
630 SZ 0/0/630 0 0.358 NA
1702 BD+SZ 0/2/1700 0.0005 0.448 0.554 (0.0779–53.935)
942 CTRL 0/2/940 0.001
rs147294857:C4T 35280227 3′-UTR C4T 931 BD 0/34/897 0.0185 0.269 0.775 (0.4932–1.219)
939 CTRL 0/44/895 0.0239
ss825678897:A4G 35279202 3′-UTR A4G 932 BD 0/3/929 0.0016 0.489 1.519 (0.2534–9.098)
943 CTRL 0/2/941 0.001
rs3812779:C4T 35276479 3′-UTR C4T 930 BD 0/1/929 0.0005 0.491 NA
944 CTRL 0/0/944 0
Abbreviations: BD, bipolar disorder; chr, chromosome; CI, conﬁdence interval; CTRL, control; MAF, minor allele frequency; NA, not applicable; OR, odds ratio; SZ, schizophrenia; UTR, untranslated
region.
The genomic reference sequence used is GRCh37/hg19; change, the base change indicated is on the negative strand; genotype count, number of homozygotes for the minor allele/heterozygotes/
homozygotes for the major allele; N, total number of research subjects; P,s i g n i ﬁcance value for a two-tailed χ2-test and Fisher’s exact test when cell frequencies were o10.
Table 4 Combined analysis of recurrent SLC1A2 variants in BD and
SZ
Description of analysis Variants included Controls
BD and
SZ P
Case-only non-synonymous rs145827578:G4A( p .
(G6S)) and rs199599866:
G4A(p.(R31Q))
0/943 7/1697 0.0458
All case-only variants rs145827578:G4A( p .
(G6S)) rs199599866:
G4A (p.(R31Q)) and
ss825678885:G4T( p .
(A20S)/5′-UTR)
0/944 9/1697 0.0189
Abbreviations: BD, bipolar disorder; SZ, schizophrenia.
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control subject. These variants are extremely rare and they will have to
be genotyped in substantially larger cohorts to understand the
potential role of these variants in susceptibility to these diseases.
However, combined analysis of the recurrent case-only non-synon-
ymous SNPs in the main SLC1A2 isoform in BD and SZ showed
evidence for association with the two diseases together (P=0.0458).
The combined association ﬁndings for the recurrent case-only variants
were strengthened when ss825678885:G4T, a 5′-UTR variant in one
isoform, and a non-synonymous variant in a different isoform was
included in the analysis (P=0.0189) and this may indicate that
disruption of the expression of SLC1A2 (discussed above) and/or the
presence of missense variants in the N-terminal portion of the EAAT2
protein leads to increased susceptibility of developing BD and/or SZ.
These tests of association have not been corrected for multiple testing and
were performed post-hoc and therefore should be considered exploratory.
However, it would be worthwhile investigating the effects of these rare
variants on the function of EAAT2 to understand their contribution to
the pathophysiology of disease in the carriers of these alleles.
While we have performed a systematic screen of the SLC1A2 gene it
is also possible that the N-terminal region of EAAT2 may harbour
additional susceptibility variants for BD and SZ. The presence of new
variants such as these will be revealed by large scale screening of this
region either using a targeted approach or as part of whole exome or
whole genome sequencing project.
We were not able to replicate the inﬂuence of rs4354668:A4Co n
the efﬁcacy of lithium46 or the association of rs4755404:C4G with
attempted suicide.45 These conﬂicting ﬁndings are not uncommon in
the genetics of complex disease and may be due to differences in the
genetic backgrounds of the samples or of sample size.
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